Gavorestat

DB16707InvestigationalSmall molecule

Gavorestat is under investigation in clinical trial NCT04902781 (Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia).

Chemical structure of Gavorestat
Formula / weight
C17H10F3N3O3S2 · 425.4 g/mol (avg)
Also known as
2-(4-Oxo-3-((5-(Trifluoromethyl)Benzo[D]Thiazol-2-Yl)Methyl)-3,4-Dihydrothieno[3,4-D]Pyridazin-1-Yl)Acetic Acid · Govorestat
Code names
AT-007

Resolves to

Compound
UNII6JLQ8K35KKCAS2170729-29-8ChEMBLCHEMBL4650327
Clinical / RWD
ATCA16AX24
Structure
InChIKeyORQGHAJIWGGFJK-UHFFFAOYSA-NSMILESOC(=O)CC1=NN(CC2=NC3=CC(=CC=C3S2)C(F)(F)F)C(=O)C2=CSC=C12
Targets
P15121AKR1B1

What you can answer from here — as of April 28, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1ATC codeIncluding every combination product, plus 2 drug categories
Sign in

Which drugs share a target with Gavorestat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In